SchizophreniaNCT03466112
Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia
A study testing endurance training and balance and tone program in people with Schizophrenia, run by Ludwig-Maximilians - University of Munich at 1 site in Germany.
Trial summary
The study investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Schizophrenia
- What is being tested?
- endurance training and balance and tone program
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteGermany
- Study dates
- Jun 2016to Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Informed consent given by the subject; DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90); age 18 to 65 years, male or female; PANSS at baseline: total score ≤ 75, proper contraception in female patients of childbearing potential; treatment with one or two antipsychotics in a stable dose of at least two weeks, body mass index between 18 and 40.
Who cannot join
- Lack of accountability; positive urine drug-screening for illicit drugs at screening (except benzodiazepines); serious suicidal risk at screening visit; other relevant interferences of axis 1 according to diagnostic evaluation (MINI); other relevant neurological or other medical disorders; pregnancy or lactation.
Trial locations and contacts
1 site in 1 country.
About this study
The study investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia.
Read the detailed description
This multi-center, two-arm, parallel-group, randomized placebo-controlled add-on clinical trial investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia. The aim is the enhancement of recovery with the use of 26 weeks of continuos endurance training (aerobic exercise) with stationary bicycles or a balance and tone program consisting of exercises for flexibility, core strength, balance and relaxation. Followed by a follow-up period of 26 weeks.
- Conditions
- Schizophrenia
- Being tested
- endurance training, balance and tone program
- Keywords
- exercise
- Medical subject headings
- Schizophrenia, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
endurance trainingOther
Also called aerobic exercise
endurance training with stationary bicycles
balance and tone programOther
flexibility, core strength, balance, relaxation
| Study group | Role | What they receive |
|---|---|---|
| endurance training | Experimental | endurance training with stationary bicycles Receives: Other: endurance training |
| balance and tone program | Active comparator | flexibility, core strength, balance, relaxation Receives: Other: balance and tone program |
What is being measured
The primary outcome is the main question the study is designed to answer.
all-cause discontinuation
Reason of study discontinuation will be identified. The all-cause-discontinuation questionnaire will be called up 9 times from baseline up to 12 months (compare time frame) including 26 weeks of intervention and 26 weeks follow up period. Reasons are defined as (1) relevant worsening of clinical symptoms (PANSS total score above 75 on cancerous visits for more than 14 days. (2) failure to take the prescribed medication for more than 14 days. (3) Failure to comply scheduled study or diagnostic appointments for more than 6 weeks (4) Patient unavailability despite extensive efforts of the treatment team (5) Withdrawal of patient consent (6) Clinician discontinuation.
Measured: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Secondary outcomes (28)
improvement in neurocognition (VLMT)
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Verbal Learning and Memory Test (VLMT).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in neurocognition (DSST)
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using a test of verbal declarative episodic memory, the Digit Symbol Substitution Test (DSST).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in neurocognition (TMT)
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Trail Making Test A and B (TMT) as a test of executive functions, quick visual comprehension, attention, and processing speed.
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in neurocognition (B-CATS)
The partial aspect of verbal fluid from the letter Cognitive Assessment Tool for Schizophrenia (B-CATS) is also used in the neuropsychological investigation at the main measurement times (at baseline, day 98, day 182 and day 365).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in neurocognition (MASC)
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Facial Affect Recognition (AOP) and Theory of Mind methods. These are tasks using the Movie for the Assessment of Social Cognition (MASC).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in psychopathology (PANSS)
The assessment of psychopathology on the basis of a patient interview takes place at all main measurement times. At baseline, day 98, 182 and day 365. The PANSS uses a standard procedure for assessing schizophrenia symptoms, which measures the severity of individual symptoms as well as the various symptom subgroups of positive and negative symptoms and general psychopathology.
Measured: 12 months (At baseline, day 98, 182 and day 365)
improvement in psychopathology (CGI)
The Clinical Global Impression Scale (CGI) assesses the overall symptom severity and response to interventions or therapies for psychiatric conditions to assess the effectiveness of the measures applied. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
Measured: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
improvement in psychopathology (SOFAS)
The Social and Occupational Functioning Assessment Scale (SOFAS) estimates social and professional performance. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
Measured: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
improvement in psychopathology (GAF)
The Social Assessment of Functioning Scale (GAF) also estimates social and professional performance. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Measured: 12 months (At baseline, day 98, 182 and day 365)
improvement in psychopathology (BSI-53)
The Brief Symptom Inventory (BSI-53) records the symptoms using 53 items. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Measured: 12 months (At baseline, day 98, 182 and day 365)
improvement in psychopathology (CDSS)
The Calgary Depression Scale for Schizophrenia (CDSS) measures suicidality and severity of depressive symptoms. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
Measured: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
improvement in social and occupational functioning (UPSA-B)
The University of California San Diego Performance-based Skills Assessment (UPSA-B) will be used to assess the day-to-day functioning of patients with schizophrenia in the household, communications, finance, transportation, and leisure activities role play situations. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in social and occupational functioning (FROGS)
Functional Remission of General Schizophrenia (FROGS) is used as a tool to measure changes in functional levels. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in social and occupational functioning (PSP)
The Personal and Social Performance Scale (PSP) is also a tool to measure changes in functional levels. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in quality of life
Only at the beginning and end of the intervention, and after one year, is the World Health Organization's Quality of Life Questionnaire (WHOQOL-Bref) used to record quality of life (The WHOQOL Group, 1998).
Measured: 12 months (at baseline, day 182 and day 365)
improvement in body mass index (BMI)
Also, the body height (in meter) and weight (in kg) of the study participants are measured. Thereupon the BMI is calculated from the body weight (kg) divided by the square of the height (m2). The unit of BMI is kg / m2.
Measured: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
change of connectivity analysis (MRI of the brain)
At four time points, just prior to initiation of V1, V4, V6 after the end of the intervention and at V9 after the follow-up period of 6 months, structural and functional MRI (fMRI) examinations are performed on a 3 Tesla whole-body MR scanner in patients and healthy control subjects (Siemens) made.
The findings are compared with data from healthy controls and non-diseased first-degree relatives of patients with schizophrenia who have been evaluated in other BMBF-funded studies ("MooDS", "IntegraMent"). In addition, cross-sectional comparisons (TAU + Exercise vs. TAU + BKGT) and progress measurements to characterize treatment effects are planned. The measurements are divided into 2 appointments to reduce the burden on patients and subjects by the measurement time.
Measured: 12 months (at baseline, day 98, day 182 and day 365)
change of volumes of brain regions (MRI)
First, structural measurements (T1 sequence, duration: approx. 5 minutes) and investigations of the fiber connections in the brain by means of diffusion-weighted imaging (DTI, duration: approx. 10 minutes) are carried out.
Measured: 12 months (at baseline, day 98, day 182 and day 365)
change of brain function (MRI)
By means of fMRI, the tasks resting activity, working memory, episodic memory, reward processing, social perspective takeover, emotion processing as well as ability to inhibit are to be investigated with already well pre-examined tasks.
A function measurement is performed at rest without stimulation (rsMRT), which provides information on the functional networking of different brain regions at rest (duration: approx. 5 minutes). There are also three fMRI surveys that record brain activity during simple psychological tasks. - The ability to inhibit (prefrontal cortex, anterior cingulate gyrus) is examined by means of a so-called flanker task. This is to respond to a specific target stimulus, which is surrounded by either the same (congruent) or by distracting (incongruent) stimuli. - Duration: 11 minutes
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement of endurance capacity
As part of the sports medical stress test, the determination of endurance performance in patients and control subjects takes place. For this examination, like in training, finder bike use and measurements of heart rate, lactate concentration and exertion sensation are performed. The ergometry is carried out as a Vita maxima examination, so it ends when the subjects can not or do not want to keep pedaling or when the termination criteria according to Steinacker \& Liu (2002) occur. From the examination, various submaximal and maximal parameters can be determined, have the validity for endurance performance and the training intensity can be determined. The examination is carried out under standardized and safe conditions and after a detailed medical history and physical examination to exclude contraindications.
Activity meters are used to control the physical activity of study participants outside the study intervention.
Measured: 12 months (at baseline, day 98, day 182 and day 365)
change of medication and attitude of the study participants to therapy (DAI)
Also, the attitude of the study participants to therapy and medication is recorded. For this, the Drug Attitude Inventory (DAI) is used. Is takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
change of medication and attitude of the study participants to therapy (SES)
The Service Engagement Scale (SES), which assesses accessibility, cooperation, help seeking and adherence, is used. It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
improvement in metabolic parameters
The laboratory diagnostic measures include a laboratory blood test, with evaluation of blood lipid levels, the C-reactive protein, glycohemoglobin (HBA1c). It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
urine (testing pregnancy and drug abuse)
Examination of the urine at baseline excludes pregnancy and drug abuse.
Measured: baseline
gene expression
Investigation of gene expression takes place at baseline.
Measured: baseline
change of genome-wide epigenetics
Investigation of genome-wide epigenetics takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
change of proteomics
Investigation of proteomics at the main measurement times (at baseline, day 98, day 182 and day 365).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
change of BDNF level
Investigation of BDNF levels at the main measurement times (at baseline, day 98, day 182 and day 365).
Measured: 12 months (at baseline, day 98, day 182 and day 365)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2018
- Study startJun 2016
- Primary completionDec 2021
- Study completionDec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 180 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ludwig-Maximilians - University of Munich
- Sponsor type
- University, hospital or other
- Collaborators
- RWTH Aachen University, Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, Central Institute of Mental Health, Mannheim
- Responsible party
- Principal investigator, Prof. Peter Falkai, Ludwig-Maximilians - University of Munich
- Investigators
- Peter G. Falkai, Prof. Dr., Principal investigator, LMU Munich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03466112
- Sponsor's protocol ID
- Version (V) 2.0 - 30.07.2018
- Status last verified
- Feb 2022
- First submitted
- 19 Feb 2018
- Last updated
- 3 Mar 2022
- Results posted
- No
Publications
Schwaiger R, Maurus I, Lembeck M, Papazova I, Greska D, Muenz S, Sykorova E, Thieme CE, Vogel BO, Mohnke S, Huppertz C, Roeh A, Keller-Varady K, Malchow B, Walter H, Wolfarth B, Wolwer W, Henkel K, Hirjak D, Schmitt A, Hasan A, Meyer-Lindenberg A, Falkai P, Roell L. Predictors of adherence to exercise interventions in people with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2024 Sep;274(6):1265-1276. doi: 10.1007/s00406-024-01789-w. Epub 2024 Mar 29.
PubMed 38551773Roell L, Keeser D, Papazov B, Lembeck M, Papazova I, Greska D, Muenz S, Schneider-Axmann T, Sykorova EB, Thieme CE, Vogel BO, Mohnke S, Huppertz C, Roeh A, Keller-Varady K, Malchow B, Stoecklein S, Ertl-Wagner B, Henkel K, Wolfarth B, Tantchik W, Walter H, Hirjak D, Schmitt A, Hasan A, Meyer-Lindenberg A, Falkai P, Maurus I. Effects of Exercise on Structural and Functional Brain Patterns in Schizophrenia-Data From a Multicenter Randomized-Controlled Study. Schizophr Bull. 2024 Jan 1;50(1):145-156. doi: 10.1093/schbul/sbad113.
PubMed 37597507Maurus I, Roell L, Keeser D, Papazov B, Papazova I, Lembeck M, Roeh A, Wagner E, Hirjak D, Malchow B, Ertl-Wagner B, Stoecklein S, Hasan A, Schmitt A, Meyer-Lindenberg A, Falkai P. Fitness is positively associated with hippocampal formation subfield volumes in schizophrenia: a multiparametric magnetic resonance imaging study. Transl Psychiatry. 2022 Sep 16;12(1):388. doi: 10.1038/s41398-022-02155-x.
PubMed 36114184Roell L, Maurus I, Keeser D, Karali T, Papazov B, Hasan A, Schmitt A, Papazova I, Lembeck M, Hirjak D, Sykorova E, Thieme CE, Muenz S, Seitz V, Greska D, Campana M, Wagner E, Loehrs L, Stoecklein S, Ertl-Wagner B, Poemsl J, Roeh A, Malchow B, Keller-Varady K, Meyer-Lindenberg A, Falkai P. Association between aerobic fitness and the functional connectome in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022 Oct;272(7):1253-1272. doi: 10.1007/s00406-022-01411-x. Epub 2022 Apr 30.
PubMed 35488054Maurus I, Hasan A, Schmitt A, Roeh A, Keeser D, Malchow B, Schneider-Axmann T, Hellmich M, Schmied S, Lembeck M, Keller-Varady K, Papazova I, Hirjak D, Topor CE, Walter H, Mohnke S, Vogel BO, Wolwer W, Schneider F, Henkel K, Meyer-Lindenberg A, Falkai P. Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial. Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):315-324. doi: 10.1007/s00406-020-01175-2. Epub 2020 Aug 3.
PubMed 32748261
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia
- ClinicalTrials.gov ID
- NCT03466112
- Acronym / sponsor ID
- Version (V) 2.0 - 30.07.2018
- Conditions
- Schizophrenia
- Keywords
- exercise
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 180 participants (actual)
- Lead sponsor
- Ludwig-Maximilians - University of MunichUniversity, hospital or other
- Collaborators
- RWTH Aachen University, Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, Central Institute of Mental Health, Mannheim
- Study start
- Jun 2016 (actual)
- Primary completion
- Dec 2021 (actual)
- Study completion
- Dec 2021 (actual)
- First posted
- 15 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia.
Detailed description
This multi-center, two-arm, parallel-group, randomized placebo-controlled add-on clinical trial investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia. The aim is the enhancement of recovery with the use of 26 weeks of continuos endurance training (aerobic exercise) with stationary bicycles or a balance and tone program consisting of exercises for flexibility, core strength, balance and relaxation. Followed by a follow-up period of 26 weeks.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| endurance training | Experimental | Other: endurance trainingendurance training with stationary bicycles |
| balance and tone program | Active comparator | Other: balance and tone programflexibility, core strength, balance, relaxation |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Informed consent given by the subject; DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90); age 18 to 65 years, male or female; PANSS at baseline: total score ≤ 75, proper contraception in female patients of childbearing potential; treatment with one or two antipsychotics in a stable dose of at least two weeks, body mass index between 18 and 40.
Key exclusion criteria (1 listed)
- Lack of accountability; positive urine drug-screening for illicit drugs at screening (except benzodiazepines); serious suicidal risk at screening visit; other relevant interferences of axis 1 according to diagnostic evaluation (MINI); other relevant neurological or other medical disorders; pregnancy or lactation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| endurance trainingAlso: aerobic exerciseendurance training with stationary bicycles | Other | endurance training |
| balance and tone programflexibility, core strength, balance, relaxation | Other | balance and tone program |
Primary outcome
all-cause discontinuation
Time frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Reason of study discontinuation will be identified. The all-cause-discontinuation questionnaire will be called up 9 times from baseline up to 12 months (compare time frame) including 26 weeks of intervention and 26 weeks follow up period. Reasons are defined as (1) relevant worsening of clinical symptoms (PANSS total score above 75 on cancerous visits for more than 14 days. (2) failure to take the prescribed medication for more than 14 days. (3) Failure to comply scheduled study or diagnostic appointments for more than 6 weeks (4) Patient unavailability despite extensive efforts of the treatment team (5) Withdrawal of patient consent (6) Clinician discontinuation.
28 secondary outcomes
improvement in neurocognition (VLMT)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in neurocognition (DSST)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in neurocognition (TMT)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in neurocognition (B-CATS)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in neurocognition (MASC)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in psychopathology (PANSS)
Time frame: 12 months (At baseline, day 98, 182 and day 365)
improvement in psychopathology (CGI)
Time frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
improvement in psychopathology (SOFAS)
Time frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
improvement in psychopathology (GAF)
Time frame: 12 months (At baseline, day 98, 182 and day 365)
improvement in psychopathology (BSI-53)
Time frame: 12 months (At baseline, day 98, 182 and day 365)
improvement in psychopathology (CDSS)
Time frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
improvement in social and occupational functioning (UPSA-B)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in social and occupational functioning (FROGS)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in social and occupational functioning (PSP)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in quality of life
Time frame: 12 months (at baseline, day 182 and day 365)
improvement in body mass index (BMI)
Time frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
change of connectivity analysis (MRI of the brain)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
change of volumes of brain regions (MRI)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
change of brain function (MRI)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement of endurance capacity
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
change of medication and attitude of the study participants to therapy (DAI)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
change of medication and attitude of the study participants to therapy (SES)
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
improvement in metabolic parameters
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
urine (testing pregnancy and drug abuse)
Time frame: baseline
gene expression
Time frame: baseline
change of genome-wide epigenetics
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
change of proteomics
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
change of BDNF level
Time frame: 12 months (at baseline, day 98, day 182 and day 365)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2022.
- Derived from this study: PubMed 38551773Schwaiger R, Maurus I, Lembeck M, Papazova I, Greska D, Muenz S, Sykorova E, Thieme CE, Vogel BO, Mohnke S, Huppertz C, Roeh A, Keller-Varady K, Malchow B, Walter H, Wolfarth B, Wolwer W, Henkel K, Hirjak D, Schmitt A, Hasan A, Meyer-Lindenberg A, Falkai P, Roell L. Predictors of adherence to exercise interventions in people with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2024 Sep;274(6):1265-1276. doi: 10.1007/s00406-024-01789-w. Epub 2024 Mar 29.
- Derived from this study: PubMed 37597507Roell L, Keeser D, Papazov B, Lembeck M, Papazova I, Greska D, Muenz S, Schneider-Axmann T, Sykorova EB, Thieme CE, Vogel BO, Mohnke S, Huppertz C, Roeh A, Keller-Varady K, Malchow B, Stoecklein S, Ertl-Wagner B, Henkel K, Wolfarth B, Tantchik W, Walter H, Hirjak D, Schmitt A, Hasan A, Meyer-Lindenberg A, Falkai P, Maurus I. Effects of Exercise on Structural and Functional Brain Patterns in Schizophrenia-Data From a Multicenter Randomized-Controlled Study. Schizophr Bull. 2024 Jan 1;50(1):145-156. doi: 10.1093/schbul/sbad113.
- Derived from this study: PubMed 36114184Maurus I, Roell L, Keeser D, Papazov B, Papazova I, Lembeck M, Roeh A, Wagner E, Hirjak D, Malchow B, Ertl-Wagner B, Stoecklein S, Hasan A, Schmitt A, Meyer-Lindenberg A, Falkai P. Fitness is positively associated with hippocampal formation subfield volumes in schizophrenia: a multiparametric magnetic resonance imaging study. Transl Psychiatry. 2022 Sep 16;12(1):388. doi: 10.1038/s41398-022-02155-x.
- Derived from this study: PubMed 35488054Roell L, Maurus I, Keeser D, Karali T, Papazov B, Hasan A, Schmitt A, Papazova I, Lembeck M, Hirjak D, Sykorova E, Thieme CE, Muenz S, Seitz V, Greska D, Campana M, Wagner E, Loehrs L, Stoecklein S, Ertl-Wagner B, Poemsl J, Roeh A, Malchow B, Keller-Varady K, Meyer-Lindenberg A, Falkai P. Association between aerobic fitness and the functional connectome in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022 Oct;272(7):1253-1272. doi: 10.1007/s00406-022-01411-x. Epub 2022 Apr 30.
- Derived from this study: PubMed 32748261Maurus I, Hasan A, Schmitt A, Roeh A, Keeser D, Malchow B, Schneider-Axmann T, Hellmich M, Schmied S, Lembeck M, Keller-Varady K, Papazova I, Hirjak D, Topor CE, Walter H, Mohnke S, Vogel BO, Wolwer W, Schneider F, Henkel K, Meyer-Lindenberg A, Falkai P. Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial. Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):315-324. doi: 10.1007/s00406-020-01175-2. Epub 2020 Aug 3.
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter G. Falkai, Prof. Dr. principal investigator
LMU Munich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing endurance training and balance and tone program in people with Schizophrenia, run by Ludwig-Maximilians - University of Munich at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
all-cause discontinuation (time frame: 12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03466112, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2022.